Solving the Unsolved in Mass Spec; Agilent Innovation and Collaboration For Today's Lab

John’s work in mass spectrometry began in the early 1980’s at Brigham Young Univ. where he received his Ph.D. under Prof. Milton Lee.  He joined HP/Agilent in 1984 and has held many many technical and management R&D positions.  John lead the instrument development teams for Agilent’s launch of triple quad and quadrupole time-of-flight mass spectrometers in 2006 followed by subsequent product releases. From 2009 - 2012 John served as GM and then Agilent VP of the LC/MS business. Since 2014 John has lead Agilent’s ion mobility program and mass spec intellectual property. In 2018 he was honored by receiving the title of Agilent Distinguished Scientist. In his spare time, he enjoys photography, waterskiing and spending time with his dear wife, their 4 children and 13 grandchildren.

Kaylie Kirkwood is a second-year chemistry PhD student in Dr. Erin Baker’s lab at North Carolina State University (NCSU). Thus far, her research has been focused on the development of multidimensional lipid spectral libraries for the rapid and confident identification of lipid species in complex samples. This work is essential for current and future applications in the Baker lab and the broader lipidomics community. Kaylie studies both clinical and environmental applications ranging from elucidating lipid markers associated with smoke inhalation injury to evaluating lipid dysregulation following exposure to perfluoroalkyl substances (PFAS). She is a trainee in the NIH/NCSU Molecular Biotechnology Training Program and is currently serving as the Communications Committee Chair of Females in Mass Spectrometry (FeMS). Prior to graduate school, Kaylie completed a B.S. in chemistry with a minor in biological sciences at NCSU. As an undergraduate researcher in Dr. David Muddiman’s lab, she utilized capillary electrophoresis-mass spectrometry for the measurement of small molecules associated with neurodegenerative diseases.

Peter is a pre-sales Application Engineer with Agilent Technologies.  He has been with Agilent for 10 years developing LC, RapidFire, and mass spec methods on a wide range of molecules.  Prior to Agilent, Peter worked in analytical development groups for BioTove and BIOCIUS, the original companies that developed the RapidFire platform.  In his spare time, you can find Peter relaxing with his wife and kids in Beverly Massachusetts, trying to fix the many problems with his home, or staying active outdoors.

Joe is a Distinguished Professor of Biochemistry and Biophyics at Oregon State University and a cofounder of e-MSion, Inc.  Joe was an undergraduate at the University of Colorado, a Captain in the US Army Medical Service Core and received his Ph.D. from Duke University.  He became a Professor in the Departments of Anesthesiology and Biochemistry at the University of Alabama at Birmingham, before moving in 2001 to Oregon State as the Ava Helen Pauling Endowed Professor.  He discovered the oxidant peroxynitrite (ONOO-) formed from superoxide and nitric oxide and nitrotyrosine, a common oxidative protein modification in pathology. He has shown protein nitration is a major pathological process mediating pathological processes as diverse as Amyotrophic Lateral Sclerosis and acute lung injury with respiratory viral infections. Shortly, after arriving at Oregon State, Joe began collaborating with Valery Voinov and Doug Barofsky to improve the mapping of oxidative protein modifications, which led to the development of electron-based fragmentation technology being commercialized at e-MSion in collaboration with Agilent Technologies for the past decade.  The technology development has been supported by six SBIR awards from NIH.  Joe enjoys skiing and white water rafting in the Pacific Northwest in between writing grant applications.

Caroline is an LC/MS Application Scientist has been with Agilent for 9 years, supporting the LC-Q/TOF, QQQ, and IM-QTOF MS.  In addition to the mass spec platforms she also supports the automation platforms, including AssayMap and Rapid Fire.  At Agilent, Caroline covers the BioPharma applications including intact proteins, native MS, glycomics, high-throughput screening and the life science applications including proteomics, targeted proteomics and metabolomics.  Prior to joining Agilent she completed her Ph.D in Biophysics at the University of California, Davis, working on clinical glycomics with high resolution MS.  Caroline then completed her post-doctoral work at the Institute for Systems Biology in Seattle, WA working on targeted proteomics and peptide quantitation of the human proteome for the Human SRM Atlas.  

Daniel Cuthbertson is a Field Application Scientist at Agilent Technologies. He is recognized internationally for his consulting for ‘omics applications and chemometric applications in food and the environment. He has a strong background in multivariate statistics, experimental design, and is an expert in LCMS method development. Dan is passionate about mass spectrometry education and teaches courses on statistical analysis of mass spectrometry data. He received his Ph.D. at Washington State University where he worked on food metabolomics and natural product structure elucidation. At home he enjoys gardening, mushroom hunting and his time as a NCAA soccer referee. 

Karen E. Yannell is a LC/MS Application Engineer at Agilent Technologies. She is an expert in small molecule high throughput analysis by triple quadrupole (TQ) and quadrupole time-of-flight (QTOF) mass spectrometry for applied markets. Her recent work has focused on developing routine Q-TOF workflows for both expert and non-expert users alike. Previously, Karen worked on forensic, metabolomics, and biomarker discovery applications with ambient ionization sources. She received her PhD in Analytical Chemistry from Purdue University where studied under the advisement of Prof. R. Graham Cooks. Outside of the laboratory, she enjoys cooking unique dishes and hiking along the beach with her dog.

M.S. and Ph.D. in Chemical Physics from Moscow Institute of Physics and Technology (1982). 
Post-doctoral training in Analytical Chemistry, The Johns Hopkins University, Baltimore, MD (1991-1993).
Research Scientist, The Johns Hopkins University, Baltimore, MD (1994-1997).
Chief Scientist, Science & Engineering Services Inc., Columbia, MD (1997 – 2014). 
Chief Executive Officer, MassTech Inc., Columbia, MD, 2014 - present. 
Over 100 publications in peer-reviewed journals, 25 patents.

B.S. and M.S. in Physics/Biophysics from Moscow Institute of Physics and Technology. 
Ph.D. in Laser Mass Spectrometry from Institute for Spectroscopy (Moscow, Russia) -1994
Post-doctoral training, George Washington University, Wash DC 1997-98
Senior Scientist, Barnett Institute at Northeastern University, Boston MA, 1999-2007
Principal Scientist, MassTech Inc. (Columbia MD) 2007- present. 
Over 50 publications in peer-reviewed journals, over 70 conference presentations. 3 patents. 
 

I am 39 years old, worked for SES and now Masstech, Inc. I have been the head of marketing and business development for a little under 2 years. I graduated from William and Mary with a bachelor’s degree in Economics, and have worked extensively in the investment industry, as well as an accountant.

Paul Auger is currently a Senior Scientist in the DMPK department at Denali Therapeutics where he oversees the internal discovery and quantitative proteomic pipeline in support of discovery biology and development sciences. His group develops quantitative assays for both potential diagnostic and phamacodynamic targets to support the biomarker strategies of therapeutic molecules in the clinic. His team also supports the discovery of new target biomarkers through the use of multi-omic analyses: combining metabolomic, lipidomic, and genomic data with unbiased and targeted discovery proteomics. Prior to joining Denali Paul held multiple industry positions including similar roles with Genentech, Amgen, and Human Genome Sciences.Paul obtained his Undergraduate degree from St. Mary’s College of Maryland and his Masters from Johns Hopkins University.
 

Dr. Linfeng Wu received her Ph.D. in 2007 at University of Connecticut for Biomedical Sciences. After a post-doc training in Dr. Michael Snyder’s group at Stanford University, she worked as a research scientist in biotech industry. Dr. Wu joined Agilent in 2015 as an application scientist, focusing on LC/MS-based analysis for protein, proteomics and small molecule analysis.

Patrick Cronan is an LC applications Scientist with Agilent Technologies. He is an accomplished analytical chemist with over 20 years of experience in the pharmaceutical and Biopharma industries; has facilitated method transfer from HPLC to UHPLC while using LCMS to characterize large and small molecule drug-like compounds. Patrick has also worked extensively with Agilent’s 2D Chromatography system developing methods to increase throughput of biologic separations by coupling multiple techniques like SEC x IEX.  

Sheher Mohsin is a senior applications scientist at Agilent Technologies.  She received her Ph. D in physical chemistry from the University of Illinois and an MBA from Rockhurst University.  She started her career at the US Environmental Protection Agency working on dioxin analysis with high resolution mass spectrometers.  She later joined Bayer and worked in the special analysis lab using mass spectrometry to solve problems in synthesis, impurity determination and submission of final product impurity profile to regulatory agencies.  Sheher’s current focus is on lipidomics using GC, LC and SFC separations and mass spectrometry.  Sheher collaborates with academic and government researchers working on complex problems to come up with innovative, simplified workflows using the latest tools in separation and mass spectrometry.

Rebecca Glaskin is an LC/MS Application Scientist at Agilent with a focus on BioPharma applications supporting the LC-Q/TOF and IM-QTOF platforms. Prior to joining Agilent, Rebecca received her Ph.D. in analytical chemistry from Indiana University in the lab of Professor David Clemmer. While there she designed and constructed home-built instruments, pushing the limits of the mobility resolution that can be obtained with a circular drift tube for the separation of biomolecules (peptides, proteins, carbohydrates, and metabolites). While there, she also studied hydrogen/deuterium exchange of proteins in the gas-phase as a function of time and pressure. Rebecca then went to Boston University as a Postdoctoral Associate in the lab of Professor Catherine Costello to develop a database containing collision cross section values for glycans, peptides, and glycopeptides utilizing Agilent Technologies 6560 IM-QTOF. This database can be used to determine how the collision cross section is altered with the addition of individual saccharide units. The trendlines obtained from this database will be used to predict collision cross sections for glycopeptides based on the conformation and structure of the specific glycoform.

Christopher Mallis graduated from Pennsylvania State University in 2015 with his B.S. in Chemistry. He then joined Texas A&M University in 2015 to pursue his Ph.D. in Chemistry under the direction of Prof. David. H. Russell. His current research focuses on the analysis of large proteins and protein complexes by MS and IM-MS.

Cody Schwarzer is a Field System Specialist, responsible for implementation and consulting on biopharma applications with QTOF, Ion Mobility, and ExD technology, focusing on data analysis for emerging technologies.

Dr. Peter JW Stone is a Senior LC/MS Applications Scientist at Agilent Technologies. He has 20+ years within HP/Agilent of experience working with many small molecule applications related to the Pharmaceutical, Environmental, Food Safety, Clinical and Forensic application areas among others. Currently, the challenges of analyzing for quality and safety with regards to cannabis products consume his time. 

Harsha Gunawardena obtained his Ph.D. in Analytical Chemistry from Purdue University and a Master of Science degree in Analytical Chemistry from University of North Carolina. He was a post-doctoral fellow at the Lineberger comprehensive cancer center, UNC school of medicine where his research focused on refining quantitative platforms for large-scale clinical proteomics and proteogenomic analysis. He was a co-investigator for the NCI clinical proteomics tumor analysis consortium (CPTAC), the ENCODE consortium. His industry career as scientist started at Bayer Health Care providing mass spectrometry and bioanalytical support of plasma-based therapeutics. He later worked at Amgen applying proteomics methods to support biomarker programs and discovery programs in oncology and inflammation.  In his current role at Janssen R&D, Johnson & Johnson, he supports discovery early development programs that span several therapeutic modalities. 

Julie Cichelli obtained her Bachelor’s Degree from Villanova University in 2003 with a major in chemistry and a minor in mathematics.  She went on to pursue graduate school at the University of Utah, studying under Dr. Zharov, completing her Ph.D. in Organic Chemistry in 2008.  Following graduate school in 2009 she accepted a postdoctoral fellowship at the Huntsman Cancer Institute in Salt Lake City researching colon cancer under Dr. Stafforini and Dr. Topham.  Subsequently, she joined the Agilent LC/MS applications team in 2010, with a focus in clinical and forensic applications.